Evidence map›Paper›PMID 23264396›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2013

Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.

Jeremi M Carswell, Joshua H Gordon, Erica Popovsky, Andrea Hale, Rosalind S Brown

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00403390 (Generic vs. Name-Brand Levothyroxine), which is not on this map. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00403390 nacompletednot on this map

Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism

TypeinterventionalSponsorBoston Children's HospitalRan2006 to 2010Enrolled34ConditionsCongenital Hypothyroidism, HypothyroidismArmsBrand Name Levothyroxine (Synthroid), Generic formulation of Levothyroxine
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Guideline
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Evaluation and management of the child with hypothyroidism.World journal of pediatrics : WJP · 2019
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Hypothyroidism in the newborn period.Current opinion in endocrinology, diabetes, and obesity · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jeremi M CarswellDivision of Endocrinology, Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
Joshua H Gordon
Erica Popovsky
Andrea Hale
Rosalind S Brown
Boston Children's Hospital · USHarvard University · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
WIRELESS CAPSULE ENDOSCOPY TO EVALUATE THE SMALL INTESTINE M01RR002172 · NCRR · CHILDREN'S HOSPITAL BOSTON · PI MANDELL, JAMES WILLIAM · 1985 to 2008
$16.0M
Research in Development Endocrinology and MetabolismT32DK007699 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI JOEL N HIRSCHHORN · 1992 to 2026
$7.1M
NCRR NIH HHS M01 RR002172NCRR NIH HHS MO1-RR02172NCRR NIH HHS UL1 RR 025758NCRR NIH HHS UL1 RR025758NIDDK NIH HHS 5T32DK007699-23NIDDK NIH HHS T32 DK007699
6 · The paper itself

Abstract

contextIn the United States, generic substitution of levothyroxine (L-T(4)) by pharmacists is permitted if the formulations are deemed to be bioequivalent by the Federal Drug Administration, but there is widespread concern that the pharmacokinetic standard used is too insensitive.

objectiveWe aimed to evaluate the bioequivalence of a brand-name L-T(4) (Synthroid) and an AB-rated generic formulation (Sandoz, Princeton, NJ) in children with severe hypothyroidism.

designThis was a prospective randomized crossover study in which patients received 8 weeks of one L-T(4) formulation followed by 8 weeks of the other.

settingThe setting was an academic medical center. PATIENTS: Of 31 children with an initial serum TSH concentration >100 mU/L, 20 had congenital hypothyroidism (CH), and 11 had autoimmune thyroiditis.

main outcome measuresThe primary endpoint was the serum TSH concentration. Secondary endpoints were the free T(4) and total T(3) concentrations.

resultsThe serum TSH concentration was significantly lower after 8 weeks of Synthroid than after generic drug (P = .002), but thyroid hormone levels did not differ significantly. Subgroup analysis revealed that the difference in TSH was restricted to patients with CH (P = .0005). Patients with CH required a higher L-T(4) dose (P < .0004) and were younger (P = .003) but were not resistant to thyroid hormone; 15 of 16 CH patients had severe thyroid dysgenesis or agenesis on imaging. The response to generic vs brand-name preparation remained significant when adjusted for age.

conclusionsSynthroid and an AB-rated generic L-T(4) are not bioequivalent for patients with severe hypothyroidism due to CH, probably because of diminished thyroid reserve. It would therefore seem prudent not to substitute L-T(4) formulations in patients with severe CH, particularly in those <3 yr of age. Our results may have important implications for other severely hypothyroid patients in whom precise titration of L-T(4) is necessary.

Indexed as

ChildChild, PreschoolCongenital HypothyroidismCross-Over StudiesDrugs, GenericFemaleHumansMaleSeverity of Illness IndexTherapeutic EquivalencyThyrotropinThyroxineTreatment OutcomeTriiodothyronineDrugs, GenericThyrotropinThyroxineTriiodothyronine

Identifiers

PMID23264396
PMCPMC3565118
OpenAlexW1988927270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.